found that an engineered LPS-targeting fusion protein significantly boosts anti-PD-L1 therapy against CRC tumors (91), suggesting that anti-LPS treatment may promote anti-PD-L1 immunotherapy for mouse model of CRC. This evidence concerns the gene CD274 and colorectal carcinoma.